BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21598259)

  • 1. Cervical cancer screening in low- and middle-income countries.
    Ditzian LR; David-West G; Maza M; Hartmann B; Shirazian T; Cremer M
    Mt Sinai J Med; 2011; 78(3):319-26. PubMed ID: 21598259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
    Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
    Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal.
    Sankaranarayanan R; Bhatla N; Gravitt PE; Basu P; Esmy PO; Ashrafunnessa KS; Ariyaratne Y; Shah A; Nene BM
    Vaccine; 2008 Aug; 26 Suppl 12():M43-52. PubMed ID: 18945413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL; Coutlée F; Ferenczy A
    Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines.
    Almonte M; Sasieni P; Cuzick J
    Best Pract Res Clin Obstet Gynaecol; 2011 Oct; 25(5):617-29. PubMed ID: 21683657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making the case for cervical cancer prevention: what about equity?
    Tsu VD; Levin CE
    Reprod Health Matters; 2008 Nov; 16(32):104-12. PubMed ID: 19027628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to cervical cancer screening in Latin America and the Caribbean.
    Herrero R; Ferreccio C; Salmerón J; Almonte M; Sánchez GI; Lazcano-Ponce E; Jerónimo J
    Vaccine; 2008 Aug; 26 Suppl 11():L49-58. PubMed ID: 18945402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of cervical cancer prevention.
    Esselen KM; Feldman S
    Clin Obstet Gynecol; 2013 Mar; 56(1):55-64. PubMed ID: 23318570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme.
    Oteng B; Marra F; Lynd LD; Ogilvie G; Patrick D; Marra CA
    Sex Transm Infect; 2011 Feb; 87(1):52-7. PubMed ID: 20956352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical cancer screening in high- and low-resource countries: implications and new developments.
    Hoppenot C; Stampler K; Dunton C
    Obstet Gynecol Surv; 2012 Oct; 67(10):658-67. PubMed ID: 23112073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cancer control in India: taking evidence to action.
    Farooqui HH; Zodpey S
    J Public Health Policy; 2012 May; 33(2):165-72. PubMed ID: 22555096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical cancer screening in the early post vaccine era.
    Waxman AG
    Obstet Gynecol Clin North Am; 2008 Dec; 35(4):537-48; vii. PubMed ID: 19061815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
    Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.
    Ginsberg GM
    Vaccine; 2013 Nov; 31 Suppl 8():I46-52. PubMed ID: 24229719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer screening programs in low-income communities. Experiences from Ecuador. Low cost detection of HPV infection in a developing country.
    Cecchini G; Paganini G; D'Amico M; Cannone M; Bertuletti C; Barberis MC
    Pathologica; 2009 Apr; 101(2):76-9. PubMed ID: 19886552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for cervical cancer prevention in Latin America and the Caribbean.
    Muñoz N; Franco EL; Herrero R; Andrus JK; de Quadros C; Goldie SJ; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 11():L96-L107. PubMed ID: 18945407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV and cervical cancer testing and prevention: knowledge, beliefs, and attitudes among Hispanic women.
    Vanslyke JG; Baum J; Plaza V; Otero M; Wheeler C; Helitzer DL
    Qual Health Res; 2008 May; 18(5):584-96. PubMed ID: 18337618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.